Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous conditioned serum produced with an in-house kit for joint and tendon injuries
IRCT20260128068684N1Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous conditioned serum in Musculoskeletal pain, joint injury, tendinopathy and 5 more, sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Treatment safety, Pain reduction and 1 more. Started Apr 2025; status: completed.
02
Drugs
autologous conditioned serum
03
Conditions
Musculoskeletal painjoint injurytendinopathymuscle strainHerniated Lumbar Disk
Beyond the preview
Go deeper on IRCT20260128068684N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260128068684N1.